PDS Biotechnology Corp Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate
PDS Biotechnology Corp (PDSB) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate of 81.00% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate · last filed 2026-03-30
- PDS Biotechnology Corp share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2024-09-30 was 0.00%, a 100.00% decline year-over-year.
- PDS Biotechnology Corp share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2024-06-30 was 106.26%, a 26.14% decline year-over-year.
- PDS Biotechnology Corp share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2024-03-31 was 145.41%, a 2.39% increase year-over-year.
- PDS Biotechnology Corp share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2023-09-30 was 150.26%, a 48.14% increase year-over-year.
- PDS Biotechnology Corp share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2025 was 81.00%, a 40.83% decline from fiscal 2024.
- PDS Biotechnology Corp share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2024 was 136.89%, a 4.17% decline from fiscal 2023.
- PDS Biotechnology Corp share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2023 was 142.84%, a 43.37% increase from fiscal 2022.
- PDS Biotechnology Corp share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2022 was 99.63%, a 0.90% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 12 month |
|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | 81.00% 10-K · filed 2026-03-30 | |||||||
| 2024-12-31 | 136.89% 10-K · filed 2026-03-30 | |||||||
| 2024-09-30 | 0.00% 10-Q · filed 2024-11-14 | 137.07% 10-Q · filed 2024-11-14 | ||||||
| 2024-06-30 | 106.26% 10-Q · filed 2024-08-13 | 137.07% 10-Q · filed 2024-08-13 | ||||||
| 2024-03-31 | 145.41% 10-Q · filed 2025-05-14 | |||||||
| 2023-12-31 | 142.84% 10-K · filed 2025-03-27 | |||||||
| 2023-09-30 | 150.26% 10-Q · filed 2024-11-14 | 142.47% 10-Q · filed 2024-11-14 | ||||||
| 2023-06-30 | 143.87% 10-Q · filed 2024-08-13 | 142.07% 10-Q · filed 2024-08-13 | ||||||
| 2023-03-31 | 142.02% 10-Q · filed 2024-05-15 | |||||||
| 2022-12-31 | 99.63% 10-K · filed 2024-03-28 | |||||||
| 2022-09-30 | 101.43% 10-Q · filed 2023-11-14 | 99.56% 10-Q · filed 2023-11-14 | ||||||
| 2022-06-30 | 100.05% 10-Q · filed 2023-08-14 | 99.45% 10-Q · filed 2023-08-14 | ||||||
| 2022-03-31 | 99.13% 10-Q · filed 2023-05-15 | |||||||
| 2021-12-31 | 100.53% 10-K · filed 2023-03-28 | |||||||
| 2021-09-30 | 100.16% 10-Q · filed 2022-11-14 | 100.58% 10-Q · filed 2022-11-14 | ||||||
| 2021-06-30 | 100.63% 10-Q · filed 2022-08-08 | 100.59% 10-Q · filed 2022-08-08 | ||||||
| 2021-03-31 | 100.38% 10-Q · filed 2022-05-11 | |||||||
| 2020-12-31 | 97.50% 10-K · filed 2022-03-31 | |||||||
| 2020-09-30 | 0.00% 10-Q · filed 2021-11-10 | 97.00% 10-Q · filed 2021-11-10 | ||||||
| 2020-06-30 | 97.13% 10-Q · filed 2021-08-12 | 97.00% 10-Q · filed 2021-08-12 | ||||||
| 2020-03-31 | 92.56% 10-Q · filed 2021-05-13 | |||||||
| 2019-12-31 | 88.70% 10-K · filed 2021-03-18 | |||||||
| 2019-09-30 | 92.22% 10-Q · filed 2020-11-13 | 89.88% 10-Q · filed 2020-11-13 | ||||||
| 2019-06-30 | 94.43% 10-Q · filed 2020-08-13 | 88.87% 10-Q · filed 2020-08-13 | ||||||
| 2019-03-31 | 83.00% 10-Q · filed 2020-05-13 | |||||||
| 2019-03-13 | 83.00% 10-K · filed 2021-03-18 | |||||||
| 2018-12-31 | 86.33% 10-K · filed 2019-02-21 | |||||||
| 2018-09-30 | 83.60% 10-Q · filed 2019-11-07 | 0.00% 10-Q · filed 2018-11-01 | 83.60% 10-Q · filed 2019-11-07 | 89.06% 10-Q · filed 2018-11-01 | ||||
| 2018-06-30 | 0.00% 10-Q · filed 2019-08-01 | 87.82% 10-Q · filed 2018-08-01 | 0.00% 10-Q · filed 2019-08-01 | 89.06% 10-Q · filed 2018-08-01 | ||||
| 2018-03-31 | 0.00% 10-Q · filed 2019-05-14 | 90.40% 10-Q · filed 2018-05-01 | ||||||
| 2017-12-31 | 88.87% 10-K · filed 2019-02-21 | |||||||
| 2017-09-30 | 86.98% 10-Q · filed 2018-11-01 | 88.82% 10-Q · filed 2018-11-01 | ||||||
| 2017-06-30 | 85.71% 10-Q · filed 2018-08-01 | 88.93% 10-Q · filed 2018-08-01 | ||||||
| 2017-03-31 | 89.37% 10-Q · filed 2018-05-01 | |||||||
| 2016-12-31 | 77.20% 10-K · filed 2018-03-01 | |||||||
| 2016-09-30 | 71.80% 10-Q · filed 2017-11-01 | 77.96% 10-Q · filed 2017-11-01 | ||||||
| 2016-06-30 | 71.80% 10-Q · filed 2017-08-01 | 78.50% 10-Q · filed 2017-08-01 | ||||||
| 2016-03-31 | 79.80% 10-Q · filed 2017-05-03 | |||||||
| 2015-12-31 | 79.80% 10-K · filed 2018-03-01 | |||||||
| 2015-09-30 | 79.80% 10-Q · filed 2016-11-01 | 79.80% 10-Q · filed 2016-11-01 | ||||||
| 2015-06-30 | 79.80% 10-Q · filed 2016-08-03 | 79.80% 10-Q · filed 2016-08-03 | ||||||
| 2015-03-31 | 79.80% 10-Q · filed 2016-05-03 | |||||||
| 2014-12-31 | 75.54% 10-K · filed 2017-03-02 | |||||||
| 2014-09-30 | 75.00% 10-Q · filed 2015-11-06 | 75.54% 10-Q · filed 2015-11-06 | ||||||
| 2013-12-31 | 75.60% 10-K · filed 2016-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |